Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.265
Open
4.200
VWAP
4.24
Vol
87.06K
Mkt Cap
757.29M
Low
4.170
Amount
369.49K
EV/EBITDA(TTM)
--
Total Shares
354.37M
EV
1.39B
EV/OCF(TTM)
41.30
P/S(TTM)
1.63
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Show More
3 Analyst Rating
40.85% Upside
Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
40.85% Upside
Current: 4.260
Low
3.00
Averages
6.00
High
8.00
40.85% Upside
Current: 4.260
Low
3.00
Averages
6.00
High
8.00
Deutsche Bank
Fynn Scherzler
Hold
downgrade
2025-07-22
Reason
Deutsche Bank
Fynn Scherzler
Price Target
2025-07-22
downgrade
Hold
Reason
Deutsche Bank analyst Fynn Scherzler lowered the firm's price target on Evotec to EUR 6 from EUR 7 and keeps a Hold rating on the shares.
RBC Capital
Charles Weston
Outperform
maintain
2025-05-15
Reason
RBC Capital
Charles Weston
Price Target
2025-05-15
maintain
Outperform
Reason
RBC Capital analyst Charles Weston raised the firm's price target on Evotec to EUR 11.90 from EUR 11.60 and keeps an Outperform rating on the shares.
Deutsche Bank
Sell -> Hold
upgrade
2025-04-24
Reason
Deutsche Bank
Price Target
2025-04-24
upgrade
Sell -> Hold
Reason
Deutsche Bank upgraded Evotec to Hold from Sell with a price target of EUR 7, up from EUR 4. The company provided new guidance for 2025 and the medium term, "offering much-needed direction," the analyst tells investors in a research note. The firm says the guidance appears achievable. Although the projected adjusted EBITDA level is "disappointing and should lead to significant consensus earnings cuts, it should provide a reasonable floor" for the shares, contends Deutsche Bank.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$8
2024-11-07
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$8
2024-11-07
Reiterates
Strong Buy
Reason
Jefferies
Benjamin Jackson
Strong Buy
to
Hold
Downgrades
$8.7 → $3.8
2024-10-07
Reason
Jefferies
Benjamin Jackson
Price Target
$8.7 → $3.8
2024-10-07
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$11 → $8
2024-08-15
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$11 → $8
2024-08-15
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Evotec SE (EVO.O) is -11.50, compared to its 5-year average forward P/E of 465.79. For a more detailed relative valuation and DCF analysis to assess Evotec SE 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
465.79
Current PE
-11.50
Overvalued PE
2557.64
Undervalued PE
-1626.07
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
37.31
Current EV/EBITDA
25.02
Overvalued EV/EBITDA
57.99
Undervalued EV/EBITDA
16.62
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
5.19
Current PS
1.49
Overvalued PS
8.39
Undervalued PS
1.99
Financials
Annual
Quarterly
FY2025Q1
YoY :
-7.23%
210.25M
Total Revenue
FY2025Q1
YoY :
+30.06%
-23.17M
Operating Profit
FY2025Q1
YoY :
+47.89%
-33.20M
Net Income after Tax
FY2025Q1
YoY :
+46.15%
-0.19
EPS - Diluted
FY2025Q1
YoY :
-40.20%
-56.08M
Free Cash Flow
FY2025Q1
YoY :
-18.26%
13.61
Gross Profit Margin - %
FY2025Q1
YoY :
-65.34%
-10.16
FCF Margin - %
FY2025Q1
YoY :
+59.49%
-15.79
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
9.3M
Volume
Months
6-9
1
9.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EVO News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
06:20:00
Evotec cuts FY25 revenue view to EUR 760M-EUR 800M from EUR 840M-EUR 880M
2024-11-29 (ET)
2024-11-29
09:42:24
Evotec Chief Operating Officer to step down on December 31
2024-11-22 (ET)
2024-11-22
10:02:49
Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy
Sign Up For More Events
Sign Up For More Events
News
4.5
07-21BenzingaNasdaq Surges Over 100 Points; Domino's Shares Fall After Q2 Results
2.0
07-21BenzingaEvotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
7.0
07-21NASDAQ.COMEvotec SE Adjusts FY25 Revenue Guidance; Adj. EBITDA Outlook Remains Unchanged
Sign Up For More News
People Also Watch
DNOW
DNOW Inc
15.130
USD
-2.07%
SFL
SFL Corporation Ltd
9.330
USD
-0.96%
HLIT
Harmonic Inc
9.000
USD
+1.24%
UTI
Universal Technical Institute Inc
31.540
USD
+0.03%
INDV
Indivior PLC
17.140
USD
+1.96%
ADNT
Adient PLC
22.730
USD
0.00%
LNN
Lindsay Corp
137.760
USD
+0.20%
KSS
Kohls Corp
12.790
USD
-6.16%
IMCR
Immunocore Holdings PLC
35.170
USD
-0.28%
ATSG
Air Transport Services Group Inc
0
USD
-0.04%
FAQ
What is Evotec SE (EVO) stock price today?
The current price of EVO is 4.26 USD — it has increased 5.19 % in the last trading day.
What is Evotec SE (EVO)'s business?
What is the price predicton of EVO Stock?
What is Evotec SE (EVO)'s revenue for the last quarter?
What is Evotec SE (EVO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Evotec SE (EVO)'s fundamentals?
How many employees does Evotec SE (EVO). have?